Tag: peripheral artery disease
Rivaroxaban significantly reduces the risk of major amputation by 70% in...
Rivaroxaban vascular dose, 2.5 mg twice daily, plus aspirin 100 mg once daily also significantly (p=0.0003) reduces the risk of the composite outcome of...
COMPASS study of Janssen’s rivaroxaban to end early for efficacy
The phase three COMPASS trial, evaluating the efficacy and safety of rivaroxaban (Xarelto, Janssen) for the prevention of major adverse cardiac events, including cardiovascular...